We evaluated the impact of World Health Organization (WHO) classification and WHO classification-based Prognostic Scoring System (WPSS) on the outcome of patients with myelodysplastic syndrome (MDS) who underwent allogeneic stem cell transplantation (allo-SCT) between 1990 and 2006. Five-year overall survival (OS) was 80% in refractory anemias, 57% in refractory cytopenias, 51% in refractory anemia with excess blasts 1 (RAEB-1), 28% in RAEB-2, and 25% in acute leukemia from MDS (P =.001). Five-year probability of relapse was 9%, 22%, 24%a, 56%, and 53%, respectively (P <.001). Five-year transplant-related mortality (TRM) was 14%,39%,38%,34%, and 44%, respectively (P =.24). In multivariate analysis, WHO classification showed a significant effect on OS (P =.017) and probability of relapse (P =.01); transfusion dependency was associated with a reduced OS (P=.01) and increased TRM (P =.037), whereas WPSS showed a prognostic significance on both OS (P =.001) and probability of relapse (P <.001). In patients without excess blasts, multilineage dysplasia and transfusion dependency affected OS (P =.001 and P =.009, respectively), and were associated with an increased TRM (P =.013 and P =.031, respectively). In these patients, WPSS identified 2 groups with different OS and TRM. These data suggest that WHO classification and WPSS have a relevant prognostic value in posttransplantation outcome of MDS patients.
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) / Alessandrino, E. P.; Della Porta, M. G.; Bacigalupo, A.; Van Lint, M. T.; Falda, M.; Onida, F.; Bernardi, M.; Iori, A. P.; Rambaldi, A.; Cerretti, R.; Marenco, P.; Pioltelli, P.; Malcovati, L.; Pascutto, C.; Oneto, R.; Fanin, R.; Bosi, A.; Levis, A.; Bandini, G.; Casini, M.; Rossi, G.; Angelucci, E.; Baronciani, D.; La Nasa, G.; Milone, G.; Mordini, N.; Guidi, S.; Corradini, P.; Milani, R.; Morra, E.; Lambretenghi Deliliers, G.; Ciceri, F.; Castagna, L.; Narni, F.; Selleri, C.; Scimè, R.; Iannitto, E.; Musso, M.; Locatelli, F.; Martelli, F.; Visani, G.; Di Bartolomeo, P.; Cavanna, L.; Papineschi, F.; Messina, G.; Gugliotta, L.; Foà, R.; Locasciulli, A.; Majolino, I.; Chiusolo, P.; Leone, G.; Arcese, W.; Carella, A. M.; Cascavilla, N.; Mazza, P.; Bruno, B.; Boccadoro, M.; Cerno, M.; Raimondi, R.. - In: BLOOD. - ISSN 0006-4971. - 112:3(2008), pp. 895-902. [10.1182/blood-2008-03-143735]
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Rossi G.;Milani R.;Ciceri F.;
2008-01-01
Abstract
We evaluated the impact of World Health Organization (WHO) classification and WHO classification-based Prognostic Scoring System (WPSS) on the outcome of patients with myelodysplastic syndrome (MDS) who underwent allogeneic stem cell transplantation (allo-SCT) between 1990 and 2006. Five-year overall survival (OS) was 80% in refractory anemias, 57% in refractory cytopenias, 51% in refractory anemia with excess blasts 1 (RAEB-1), 28% in RAEB-2, and 25% in acute leukemia from MDS (P =.001). Five-year probability of relapse was 9%, 22%, 24%a, 56%, and 53%, respectively (P <.001). Five-year transplant-related mortality (TRM) was 14%,39%,38%,34%, and 44%, respectively (P =.24). In multivariate analysis, WHO classification showed a significant effect on OS (P =.017) and probability of relapse (P =.01); transfusion dependency was associated with a reduced OS (P=.01) and increased TRM (P =.037), whereas WPSS showed a prognostic significance on both OS (P =.001) and probability of relapse (P <.001). In patients without excess blasts, multilineage dysplasia and transfusion dependency affected OS (P =.001 and P =.009, respectively), and were associated with an increased TRM (P =.013 and P =.031, respectively). In these patients, WPSS identified 2 groups with different OS and TRM. These data suggest that WHO classification and WPSS have a relevant prognostic value in posttransplantation outcome of MDS patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
